SINGAPORE - Media OutReach - 10 November 2023 - AtkinsRéalis (TSX: ATRL), a fully integrated professional services and project management company with offices around the world, has been awarded an engineering and design services contract by WuXi STA, a subsidiary of WuXi AppTec, to support the first phase of an active pharmaceutical ingredient (API) manufacturing facility in Singapore. The facility aims to further enable WuXi STA's global partners to advance healthcare innovations by providing s
The company, which is a joint venture between WuXi Biologics and WuXi STA that provides end-to-end contract services covering antibodies and other biologics intermediates, will issue 178.4 million shares priced at a maximum of HK$20.60 each, according to the company's regulatory filing. In July, parent WuXi Biologics revealed its intentions to spin-off Wuxi XDC and initiate a separate listing for the arm. Wuxi Biologics said the separate listing would enable the unit to serve as an independent platform that would continue to focus on the company's global contract research, development, and manufacturing organization businesses, highlighting the benefits of better allocation of capital and resources if the IPO goes through.
Samsung Biologics is building a fifth plant for cell and gene therapy and mRNA vaccines. The Korean CDMO recently won FDA clearance to help make GlaxoSmithKline and Vir Biotechnology's COVID-19 antibody drug. Fujifilm is buying a new cell therapy plant. And more.